CytomX Therapeutics Inc (NASDAQ:CTMX) Reports Q2 2025 Revenue Beat and Break-Even EPS

CytomX Therapeutics Inc (NASDAQ:CTMX) reported its second-quarter 2025 financial results, delivering revenue that exceeded analyst expectations while meeting earnings per share (EPS) estimates. The company posted revenue of $18.66 million, surpassing the consensus estimate of $15.08 million. EPS came in at $0.00, slightly better than the anticipated loss of -$0.0782 per share. The market reaction has been cautiously optimistic, with shares rising approximately 0.95% in after-hours trading following the announcement.

Key Financial Highlights

• Revenue Beat: The $18.66 million in Q2 revenue represents a 23.7% increase over analyst expectations, signaling stronger-than-anticipated performance in the quarter.
• EPS in Line: While the company did not post a profit, the break-even EPS was an improvement over the projected loss, suggesting cost management may be aligning with revenue growth.
• Full-Year Estimates: Analysts currently forecast full-year 2025 revenue at $90.03 million, with an expected EPS loss of -$0.21675. The Q2 beat could lead to upward revisions if the trend continues.

Business Update & Clinical Progress

The earnings release highlighted positive interim data from the ongoing Phase 1 study of CX-2051, an EpCAM-targeting antibody-drug conjugate (ADC), in advanced colorectal cancer (CRC) patients. This development underscores CytomX’s progress in its PROBODY therapeutic platform, which aims to create tumor-localized treatments with reduced systemic toxicity.

Other key pipeline assets include:

• CX-904: A masked T-cell engager targeting EGFR and CD3, currently in early-stage trials.
• CX-801: A conditionally activated interferon alpha-2b cytokine designed for immuno-oncology applications.

Market Reaction & Outlook

Despite the revenue beat, CTMX shares have declined over the past month (-12.85%) and two weeks (-10.7%), reflecting broader market skepticism around clinical-stage biotech firms. The slight after-hours uptick suggests some investors see potential in the Q2 results, but sustained momentum will likely depend on further clinical validation.

For Q3 2025, analysts expect revenue of $11.99 million and an EPS loss of -$0.08568. CytomX did not provide formal guidance in its release, leaving investors to rely on external estimates.

Where to Find More Earnings Data

For a deeper dive into CytomX’s earnings history and future estimates, visit the earnings and estimates page.

Disclaimer: This article is not investment advice. Investors should conduct their own research or consult a financial advisor before making decisions.